Jubilant Ingrev.

What does Jubilant Ingrev. do?

Jubilant Ingrevia Ltd is a mid-cap company in the specialty chemicals industry, incorporated in 2019, with recent quarterly net sales of ₹1,051 Cr and a net profit of ₹74 Cr as of March 2025. Key metrics include a P/E ratio of 45.00 and a market cap of ₹11,275 Cr.

Overview:<BR>Jubilant Ingrevia Ltd operates in the specialty chemicals industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was incorporated as a public limited company in 2019 and changed its name from Jubilant LSI Limited to Jubilant Ingrevia Limited on October 16, 2020. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,051 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 74 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 11,275 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 45.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.70%<BR>- Debt Equity: 0.22<BR>- Return on Equity: 8.58%<BR>- Price to Book: 3.89<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Has Jubilant Ingrev. declared dividend?

Yes, Jubilant Ingrevia Ltd has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of February 3, 2025. The company has shown positive total returns over the past year (42.17%) and two years (75.75%), despite recent fluctuations.

Jubilant Ingrevia Ltd has declared a 250% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: 03 Feb 25<BR><BR>Dividend Yield: 0.7%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -7.44%, the dividend return was 0.32%, resulting in a total return of -7.12%.<BR><BR>Over the past year, the price return was 41.22%, the dividend return was 0.95%, leading to a total return of 42.17%.<BR><BR>In the 2-year period, there was a price return of 73.59%, a dividend return of 2.16%, culminating in a total return of 75.75%.<BR><BR>For the 3-year period, the price return stood at 44.57%, with a dividend return of 2.79%, resulting in a total return of 47.36%.<BR><BR>In the 4-year period, the price return was 24.23%, the dividend return was 2.84%, which gave a total return of 27.07%.<BR><BR>Over the last 5 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Jubilant Ingrevia Ltd has declared a substantial dividend, and while the recent total returns have varied significantly, the company has shown positive performance over longer periods, particularly in the 1 and 2-year spans.

Who are the peers of the Jubilant Ingrev.?

Jubilant Ingrev.'s peers include Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Anupam Rasayan, Alkyl Amines, Aether Industri., and Privi Speci. Its 1-year return is 44.16%, with management risk rated as Good and Below Average growth.

Peers: The peers of Jubilant Ingrev. are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Anupam Rasayan, Alkyl Amines, Aether Industri., and Privi Speci.<BR><BR>Quality Snapshot: Excellent management risk is observed at Deepak Nitrite and Alkyl Amines, while Good management risk is found at Pidilite Inds., SRF, Himadri Special, and Jubilant Ingrev. Average management risk is present at Gujarat Fluoroch, Anupam Rasayan, and Privi Speci., and Below Average management risk is noted at Aether Industri. Growth is Average at Pidilite Inds., SRF, and Anupam Rasayan, while Below Average growth is seen at Gujarat Fluoroch, Deepak Nitrite, Alkyl Amines, and Privi Speci., with Good growth at Himadri Special. Jubilant Ingrev. has Below Average growth. Capital Structure is Excellent at Pidilite Inds., SRF, Jubilant Ingrev., Deepak Nitrite, Alkyl Amines, and Aether Industri., while Good capital structure is found at Gujarat Fluoroch and Himadri Special, and Average at Anupam Rasayan and Privi Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Privi Speci. at 100.73%, while the lowest is Deepak Nitrite at -9.57%. Jubilant Ingrev.'s 1-year return is 44.16%, which is significantly higher than Deepak Nitrite's but lower than Privi Speci.'s. Additionally, the peers with negative six-month returns include Deepak Nitrite, Aether Industri., and Galaxy Surfact.

Who are in the management team of Jubilant Ingrev.?

As of March 2023, the management team of Jubilant Ingrev includes Shyam S Bhartia (Chairman), Hari S Bhartia (Co-Chairman), Rajesh Srivastava (Managing Director & CEO), and several independent and non-executive directors, ensuring a diverse governance structure.

As of March 2023, the management team of Jubilant Ingrev includes the following members:<BR><BR>1. Shyam S Bhartia - Chairman & Non Executive Director<BR>2. Hari S Bhartia - Co-Chairman / Non Executive Director<BR>3. S K Roongta - Independent Non Executive Director<BR>4. Sudha Pillai - Independent Non Executive Director<BR>5. Arun Seth - Independent Non Executive Director<BR>6. Pradeep Banerjee - Independent Non Executive Director<BR>7. Siraj Azmat Chaudhry - Independent Non Executive Director<BR>8. Ameeta Sonjoy - Independent Non Executive Director<BR>9. Priyavrat Bhartia - Non Executive Director<BR>10. Arjun Shanker Bhartia - Non Executive Director<BR>11. Rajesh Srivastava - Managing Director & CEO<BR>12. Mr. Deepak Jain - Managing Director & CEO<BR>13. Mr. Chandan Singh Sengar - Whole Time Director & CEO<BR><BR>This diverse team combines executive and non-executive roles, contributing to the company's governance and strategic direction.

Who are the top shareholders of the Jubilant Ingrev.?

The top shareholders of Jubilant Ingrev. include promoters holding 20.63%, mutual funds with 14.1%, foreign institutional investors at 7.12%, and individual investors owning 19.13%, with Dsp Small Cap Fund being the largest public shareholder at 9.37%.

The top shareholders of Jubilant Ingrev. include a mix of promoters, mutual funds, foreign institutional investors (FIIs), and individual investors. The majority shareholders are the promoters, with the highest holding attributed to Spb Trustee Company Pl & Ss Trustee Company Pl, which holds 20.63%. <BR><BR>In terms of mutual funds, 18 schemes collectively hold 14.1% of the company. Foreign institutional investors have a stake of 7.12%, held by 116 different FIIs. The highest public shareholder is Dsp Small Cap Fund, which holds 9.37%. Additionally, individual investors collectively own 19.13% of the company.

How big is Jubilant Ingrev.?

As of 24th July, Jubilant Ingrevia Ltd has a market capitalization of 12,517.00 Cr, with net sales of 4,177.61 Cr and a net profit of 251.17 Cr reported in the latest four quarters.

As of 24th July, Jubilant Ingrevia Ltd has a market capitalization of 12,517.00 Cr and is classified as a Mid Cap company.<BR><BR>In the latest four quarters, Jubilant Ingrevia reported Net Sales of 4,177.61 Cr and a Net Profit of 251.17 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 2,737.47 Cr and Total Assets totaling 4,719.17 Cr.

Are Jubilant Ingrev. latest results good or bad?

Jubilant Ingrevia's latest results show record revenue growth of 7.22% year-on-year, but a concerning 7.50% decline in net profit and reduced operating margins indicate cost pressures. While revenue performance is positive, investors should be cautious due to the stock's significant underperformance year-to-date.

Jubilant Ingrevia's latest results present a mixed picture. On one hand, the company achieved record revenue of ₹1,120.73 crores for Q2 FY26, reflecting a strong year-on-year growth of 7.22% and a quarter-on-quarter increase of 7.98%. This indicates a positive trend in top-line performance and suggests sustained demand recovery.<BR><BR>However, the net profit for the same quarter was ₹69.47 crores, which represents a decline of 7.50% compared to the previous quarter. This decline in profitability is concerning, especially given the revenue growth, as it indicates that the company is facing increasing cost pressures and margin compression. The operating margin also decreased to 12.21%, down from 13.81% in the previous quarter.<BR><BR>Overall, while the revenue growth is a positive sign, the sequential decline in net profit and margins raises questions about the company's ability to manage costs effectively in a challenging operating environment. Investors may need to exercise caution as the stock has underperformed significantly, trading down 17.71% year-to-date compared to the Sensex's gain of 8.50%.

Is Jubilant Ingrev. overvalued or undervalued?

As of November 7, 2025, Jubilant Ingrev. is considered overvalued with a valuation grade shift to expensive, reflected in its high PE Ratio of 36.66 and underperformance against the Sensex, with a year-to-date return of -19.49%.

As of 7 November 2025, the valuation grade for Jubilant Ingrev. has moved from fair to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 36.66, an EV to EBITDA of 19.92, and a Price to Book Value of 3.61, which are significantly higher than many of its peers.<BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla stands at a more attractive PE Ratio of 22.33 and an EV to EBITDA of 5.58. This suggests that Jubilant Ingrev. is trading at a premium relative to its industry peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -19.49% compared to the Sensex's 6.50%, further reinforcing the view that it is overvalued at its current price of 662.90.

Is Jubilant Ingrev. technically bullish or bearish?

As of November 27, 2025, Jubilant Ingrev. shows a mildly bearish trend, indicated by daily moving averages and bearish KST signals, despite some bullish momentum from weekly MACD and Bollinger Bands.

As of 27 November 2025, the technical trend for Jubilant Ingrev. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the KST showing bearish signals on both weekly and monthly time frames. While the weekly MACD and Bollinger Bands suggest some bullish momentum, the overall monthly indicators, including MACD and Dow Theory, remain mildly bearish. The stock's recent performance, with a decline of 1.51% over the past week compared to a slight gain in the Sensex, further supports the bearish sentiment.

How has been the historical performance of Jubilant Ingrev.?

Jubilant Ingrev. has shown fluctuating financial performance, with net sales of 4,177.61 Cr in March 2025, up from 4,135.80 Cr in March 2024 but down from 4,772.69 Cr in March 2023. Key metrics like operating profit and profit after tax increased from the previous year but remained lower than in March 2023.

Answer:<BR>The historical performance of Jubilant Ingrev. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Ingrev. reported net sales of 4,177.61 Cr in March 2025, a slight increase from 4,135.80 Cr in March 2024, but a decrease from 4,772.69 Cr in March 2023. The total operating income followed a similar pattern, with figures of 4,177.61 Cr in March 2025 and 4,135.80 Cr in March 2024, compared to 4,772.69 Cr in March 2023. The total expenditure, excluding depreciation, was 3,658.53 Cr in March 2025, down from 3,714.68 Cr in March 2024 and 4,225.55 Cr in March 2023. Operating profit (PBDIT) for March 2025 was 556.90 Cr, an increase from 456.42 Cr in March 2024, but lower than 580.51 Cr in March 2023. Profit before tax was 343.63 Cr in March 2025, up from 267.59 Cr in March 2024, but down from 436.75 Cr in March 2023. The profit after tax for March 2025 was 251.19 Cr, an increase from 182.87 Cr in March 2024, but lower than 307.54 Cr in March 2023. The consolidated net profit for March 2025 was 251.17 Cr, compared to 182.89 Cr in March 2024 and 307.50 Cr in March 2023. The earnings per share (EPS) rose to 15.89 in March 2025 from 11.58 in March 2024, but decreased from 19.34 in March 2023. Total assets increased to 5,015.12 Cr in March 2025 from 4,719.17 Cr in March 2024, while total liabilities also rose to 5,015.12 Cr in March 2025 from 4,719.17 Cr in March 2024. The cash flow from operating activities improved to 508.00 Cr in March 2025 from 429.00 Cr in March 2024, although the net cash outflow for March 2025 was -9.00 Cr, down from a positive inflow of 6.00 Cr in March 2024.

Should I buy, sell or hold Jubilant Ingrevia Ltd?

When is the next results date for Jubilant Ingrevia Ltd?

The next results date for Jubilant Ingrevia Ltd is February 4, 2026.

The next results date for Jubilant Ingrevia Ltd is scheduled for February 4, 2026.

Which are the latest news on Jubilant Ingrev.?

Why is Jubilant Ingrevia Ltd falling/rising?

As of 01-Feb, Jubilant Ingrevia Ltd's stock price is at 620.55, down 2.38%, with significant declines over various periods and underperformance compared to the Sensex. Despite strong fundamentals, the stock's long-term growth outlook is poor, reflected in its negative returns and trading below key moving averages.

As of 01-Feb, Jubilant Ingrevia Ltd's stock price is falling, currently at 620.55, reflecting a decrease of 15.15 or 2.38%. This decline is evident in the stock's performance over various periods, including a 1-week drop of 2.21% and a 1-month decrease of 10.76%. Year-to-date, the stock has fallen by 11.85%, significantly underperforming the benchmark Sensex, which has only declined by 5.28% in the same timeframe.<BR><BR>Today's trading activity shows that the stock opened with a gain of 2.19%, reaching an intraday high of Rs 649.65, but quickly fell to a low of Rs 615.3, indicating volatility and a lack of sustained upward momentum. The weighted average price suggests that more volume was traded closer to the low price, further indicating bearish sentiment among investors.<BR><BR>Moreover, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a negative trend. Although there has been a notable increase in delivery volume, rising by 201.1% against the 5-day average, this does not seem to translate into positive price movement.<BR><BR>While the company has demonstrated strong fundamentals, such as a low Debt to EBITDA ratio and positive results over the last four quarters, the long-term growth outlook remains poor, with an annual operating profit decline of 5.79% over the past five years. This underperformance is compounded by the stock's negative returns over the last year and its inability to keep pace with broader market indices, contributing to the current downward pressure on its price.